Pancreatic neuroendocrine neoplasms (PanNENs) are a diverse group of cancers with varying clinical presentations and prognoses due to differences in morphology and clinical stage. Most are non-functional tumors that express somatostatin receptors (SSTRs). Several treatment options have been established for patients with locally advanced or metastatic PanNETs, but the optimal choice of treatment approach and the sequence of available therapies are not yet clearly defined and are currently being studied in multiple ongoing clinical trials. Additionally, new drugs are being researched for PanNET treatment, including immune checkpoint inhibitors, next-generation peptide receptor radionuclide therapy, and other targeted biological therapies. To improve treatment outcomes for patients with PanNETs, a multidisciplinary team should evaluate systemic treatment options. The aim of this article is to review currently available therapies and discuss new and emerging systemic treatment strategies for patients with advanced PanNETs.
胰腺神经内分泌肿瘤（PanNENs）是一组异质性显著的癌症，其形态学特征与临床分期的差异导致临床表现和预后各不相同。大多数为非功能性肿瘤，表达生长抑素受体（SSTRs）。针对局部晚期或转移性胰腺神经内分泌肿瘤患者已建立多种治疗方案，但最佳治疗策略的选择及现有疗法的序贯应用尚未明确界定，目前正通过多项临床试验进行探索。此外，针对胰腺神经内分泌肿瘤的新型药物研究也在持续推进，包括免疫检查点抑制剂、新一代肽受体放射性核素治疗及其他靶向生物疗法。为提升胰腺神经内分泌肿瘤患者的治疗效果，应由多学科团队系统评估全身治疗方案。本文旨在综述现有治疗手段，并探讨晚期胰腺神经内分泌肿瘤患者的新型及新兴全身治疗策略。
New Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review
肿瘤(癌症)患者之家